AllSci News
Kazia touts 100% clinical benefit rate for paxalisib in early-stage TNBC study
A 100% clinical benefit rate across six evaluable patients with Stage IV triple-negative breast cancer (TNBC) has emerged from an ongoing Phase Ib study of...
Osivax pairs Phase II flu vaccine with GC Biopharma's marketed shot in combination deal
France-based Osivax and South Korea-based GC Biopharma (KRX: 006280) have announced a long-term collaboration to develop a single-injection combination...
FDA approves Moderna's updated 2026-2027 COVID-19 vaccines for high-risk and older adults
The US FDA has approved updated 2026-2027 formulations of both Spikevax and mNexspike (COVID-19 Vaccine, mRNA) from Cambridge, Massachusetts-based Moderna...
Genentech taps DualityBio's DUPAC platform for multi-program ADC collaboration
Genentech has licensed DualityBio's DUPAC antibody-drug conjugate payload platform in a multi-program collaboration designed to generate next-generation...
Shingrix shows potential cardiovascular benefit in US natural experiment
A large observational study exploiting a natural experiment in US vaccine policy has found that recipients of the recombinant herpes zoster vaccine Shingrix...
AbbVie seeks EMA approval for Skyrizi subcutaneous induction in Crohn's disease
AbbVie (NYSE: ABBV) has submitted an application to the European Medicines Agency (EMA) seeking approval for Skyrizi (risankizumab) subcutaneous (SC)...
Amgen/AZ's Tezspire extends TSLP platform to eosinophilic esophagitis with Phase III win
Tezepelumab has met both co-primary and all key secondary endpoints in eosinophilic esophagitis, Amgen (Nasdaq: AMGN) and AstraZeneca reported on August 27,...
Graviton/Beijing Tide’s GV101 posts 86% response rate in Phase Ib cGvHD study
Phase Ib/II data from New York-based Graviton BioScience Corporation's selective ROCK2 inhibitor GV101, published in Signal Transduction and Targeted...
TRexBio’s TNFR2 agonist shows human proof-of-mechanism in Phase I
South San Francisco-based TRex Bio, Inc. (TRexBio) has reported positive Phase Ia results for TRB-061, a selective tumor necrosis factor receptor 2 (TNFR2)...
Revolution lands first approval for RAS(ON) platform with Rasonque
The US FDA has approved Rasonque (daraxonrasib), the first-in-class pan-RAS inhibitor developed by Revolution Medicines (Nasdaq: RVMD), for adults with...
Celcuity seeks to expand Revtorpyk label to PIK3CA-mutant breast cancer after beating alpelisib
Minneapolis-based Celcuity Inc. (Nasdaq: CELC) submitted a supplemental New Drug Application (sNDA) to the US FDA for Revtorpyk (gedatolisib), seeking...
Cellenkos's Treg cell therapy CK0803 wins FDA fast track for ALS
Houston-based Cellenkos, Inc. announced receipt of US FDA Fast Track Designation for CK0803, an allogeneic cord blood-derived T-regulatory (Treg) cell...
EC approves Acadia's Daybu as first-ever Rett syndrome treatment in the EU
The European Commission has granted marketing authorization for Daybu (trofinetide), making San Diego-based Acadia Pharmaceuticals (Nasdaq: ACAD) the first...
Shanghai Minwei launches first human trial of ActRIIA/B antibody for obesity
Shanghai Minwei Biotechnology Co., Ltd. has registered a Phase I first-in-human clinical trial of MWN110, a monoclonal antibody the company said targets...
CSPC's PD-1/IL-15 fusion protein earns FDA Fast Track status for MSS/pMMR CRC
China-based CSPC Pharmaceutical Group Limited (HKEX: 01093) announced receipt of US FDA Fast Track Designation for SYS6090 (JMT108), a first-in-class...
The AllSci Brief
Free, systematic R&D and deal news. Daily.